Matches in SemOpenAlex for { <https://semopenalex.org/work/W2914716166> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W2914716166 endingPage "514" @default.
- W2914716166 startingPage "508" @default.
- W2914716166 abstract "Three commercially available assays for the measurement of antibodies to infliximab (ATI) are approved for clinical use in Australia: Promonitor anti-infliximab (Grifols), Lisa Tracker anti-infliximab (Theradiag) and Ridascreen anti-IFX (R-Biopharm). All are bridging ELISA assays. Measurement of ATI has been incorporated into treatment algorithms for assessing loss of response to infliximab in patients with inflammatory bowel disease, but results obtained by the three ATI assays have not been systematically compared. We performed a series of experiments to allow comparison of results between the assays. Forty-two patient samples known to be positive for ATI by the Lisa Tracker assay were run on the Promonitor assay in singlicate, of which 26 were run on the Ridascreen assay in duplicate, according to the manufacturers' instructions. The Spearman correlation coefficient for all three pairwise assay comparisons was 0.95. Results were not numerically comparable between the assays. The coefficient of variation (CV) was 2.3% for the Lisa Tracker assay, 7.6% for the Promonitor assay and 7.4% for the Ridascreen assay. The presence of infliximab interfered with all three assays in a dose dependent manner. The cut-point for loss of response to infliximab dose intensification, previously demonstrated to be 200 ng/mL on the Lisa Tracker assay, is equivalent to approximately 60 ng/mL on the Ridascreen assay and between 22.9 and 41 AU/mL on the Promonitor assay. All three assays are suitable for clinical use." @default.
- W2914716166 created "2019-02-21" @default.
- W2914716166 creator A5041716460 @default.
- W2914716166 creator A5048235044 @default.
- W2914716166 creator A5077446993 @default.
- W2914716166 date "2021-06-01" @default.
- W2914716166 modified "2023-09-26" @default.
- W2914716166 title "Comparison of three commercially available ELISA assays for anti-infliximab antibodies" @default.
- W2914716166 cites W2003835888 @default.
- W2914716166 cites W2013754528 @default.
- W2914716166 cites W2071885860 @default.
- W2914716166 cites W2087663450 @default.
- W2914716166 cites W2088135039 @default.
- W2914716166 cites W2113674146 @default.
- W2914716166 cites W2118559127 @default.
- W2914716166 cites W2122735365 @default.
- W2914716166 cites W2129592053 @default.
- W2914716166 cites W2136589391 @default.
- W2914716166 cites W2170364552 @default.
- W2914716166 cites W2208606346 @default.
- W2914716166 cites W2321336450 @default.
- W2914716166 cites W2340839875 @default.
- W2914716166 cites W2519393083 @default.
- W2914716166 cites W2784524664 @default.
- W2914716166 cites W2791731545 @default.
- W2914716166 cites W2916794721 @default.
- W2914716166 cites W2923576761 @default.
- W2914716166 cites W2952846675 @default.
- W2914716166 doi "https://doi.org/10.1016/j.pathol.2020.08.020" @default.
- W2914716166 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33272693" @default.
- W2914716166 hasPublicationYear "2021" @default.
- W2914716166 type Work @default.
- W2914716166 sameAs 2914716166 @default.
- W2914716166 citedByCount "3" @default.
- W2914716166 countsByYear W29147161662022 @default.
- W2914716166 countsByYear W29147161662023 @default.
- W2914716166 crossrefType "journal-article" @default.
- W2914716166 hasAuthorship W2914716166A5041716460 @default.
- W2914716166 hasAuthorship W2914716166A5048235044 @default.
- W2914716166 hasAuthorship W2914716166A5077446993 @default.
- W2914716166 hasConcept C126322002 @default.
- W2914716166 hasConcept C159654299 @default.
- W2914716166 hasConcept C17991360 @default.
- W2914716166 hasConcept C185592680 @default.
- W2914716166 hasConcept C203014093 @default.
- W2914716166 hasConcept C2777138892 @default.
- W2914716166 hasConcept C2778260677 @default.
- W2914716166 hasConcept C2779134260 @default.
- W2914716166 hasConcept C43617362 @default.
- W2914716166 hasConcept C71924100 @default.
- W2914716166 hasConcept C89838059 @default.
- W2914716166 hasConceptScore W2914716166C126322002 @default.
- W2914716166 hasConceptScore W2914716166C159654299 @default.
- W2914716166 hasConceptScore W2914716166C17991360 @default.
- W2914716166 hasConceptScore W2914716166C185592680 @default.
- W2914716166 hasConceptScore W2914716166C203014093 @default.
- W2914716166 hasConceptScore W2914716166C2777138892 @default.
- W2914716166 hasConceptScore W2914716166C2778260677 @default.
- W2914716166 hasConceptScore W2914716166C2779134260 @default.
- W2914716166 hasConceptScore W2914716166C43617362 @default.
- W2914716166 hasConceptScore W2914716166C71924100 @default.
- W2914716166 hasConceptScore W2914716166C89838059 @default.
- W2914716166 hasFunder F4320320391 @default.
- W2914716166 hasIssue "4" @default.
- W2914716166 hasLocation W29147161661 @default.
- W2914716166 hasOpenAccess W2914716166 @default.
- W2914716166 hasPrimaryLocation W29147161661 @default.
- W2914716166 hasRelatedWork W2136885623 @default.
- W2914716166 hasRelatedWork W2163972817 @default.
- W2914716166 hasRelatedWork W2200286877 @default.
- W2914716166 hasRelatedWork W2273630113 @default.
- W2914716166 hasRelatedWork W2978650559 @default.
- W2914716166 hasRelatedWork W3162050615 @default.
- W2914716166 hasRelatedWork W3209514756 @default.
- W2914716166 hasRelatedWork W4225828223 @default.
- W2914716166 hasRelatedWork W4282980674 @default.
- W2914716166 hasRelatedWork W2074509533 @default.
- W2914716166 hasVolume "53" @default.
- W2914716166 isParatext "false" @default.
- W2914716166 isRetracted "false" @default.
- W2914716166 magId "2914716166" @default.
- W2914716166 workType "article" @default.